Julie Ehlers

From 15 to 40 years after diagnosis, pediatric cancer survivors have a roughly 4-fold higher risk of death than the general population, a study suggests.

Adding zolbetuximab to chemotherapy improves survival outcomes in patients with unresectable or metastatic gastric/GEJ cancer.